


PHARMACEUTICAL 2022

MANNKIND CORP Rank 413 of 466









PHARMACEUTICAL 2022

MANNKIND CORP

Rank 413 of 466

The relative strengths and weaknesses of MANNKIND CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MANNKIND CORP compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 37% points. The greatest weakness of MANNKIND CORP is the variable Other Liabilities, reducing the Economic Capital Ratio by 231% points.

The company's Economic Capital Ratio, given in the ranking table, is -104%, being 182% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	219,744
Cost of Goods Sold	16,833
Intangible Assets	0
Liabilities, Current	48,349
Liabilities, Non-Current	25,533
Other Assets	64,805
Other Compr. Net Income	0
Other Expenses	15,902
Other Liabilities	456,628
Other Net Income	-33,904
Other Revenues	75,442
Property and Equipment	36,612
Research and Development	12,312
Selling, General and Administrative Expense	77,417

Output Variable	Value in 1000 USD
Assets	321,161
Liabilities	530,510
Expenses	122,464
Revenues	75,442
Stockholders Equity	-209,349
Net Income	-80,926
Comprehensive Net Income	-80,926
Economic Capital Ratio	-104%

